



**MONA MALIK, PhD**  
**SENIOR TECHNICAL ADVISOR AND PATENT AGENT**



Hahn Loeser & Parks LLP  
200 West Madison Street, Suite 2700  
Chicago, Illinois 60606

**p** 312.637.3023 **f** 312.637.3001  
**e** mmalik@hahnlaw.com

[hahnlaw.com](http://hahnlaw.com)

Dr. Mona Malik is a patent agent and senior technical advisor with more than a decade of experience as a law practitioner in intellectual property. Earlier in her career, Mona was a scientist for a dozen years raising to the faculty level at the University of Pennsylvania. Mona provides scientific and legal expertise in litigations involving pharmaceutical products. She was involved in Hatch-Waxman litigations for Boniva, Actonel, Megace, Zometa, Reclast and Treanda to name a few. Mona's other areas of focus include patent prosecution, due diligence assessment and freedom to operate analysis in areas such as pharmaceuticals, cellular biology and botany. She also supports clients in other science-related fields such as advising Biotechnology Companies on potential investment or growth opportunities. The scope of Mona's work includes cancer therapy immunology/immunotherapy, biochemistry, pharmacology, virology, oncology, plant sciences and agriculture.

Mona Malik earned a PhD from the University of Cambridge after investigating complex mechanisms of chromosomal gene recombination and gene replacement. As a faculty member and research associate at the University of Pennsylvania working in the Department of Pulmonary, Allergy and Critical Care at the School of Medicine, she investigated the biochemistry of intracellular signaling pathways in mononuclear phagocytes and uncovered a novel mechanism of monocyte infiltration in the central nervous system of HIV-infected patients. Mona's work in the fields of immunology, anti-cancer therapy and HIV-treatment was published in leading scientific journals.

Her work as a postdoctoral research associate at St Jude Children's Research Hospital focused on various mechanisms responsible for cell cycle regulation and the repair of DNA lesions induced by anti-cancer therapy. Mona played a critical role in research for the advancement of cancer therapies. She defined the function of the Tyrosyl-DNA Phosphodiesterase enzyme in the repair of DNA-damage induced by DNA Topoisomerase II inhibitors, an important class of anti-cancer drugs. Her work was seminal in the further development of DNA assays to possibly use mutations of the gene Tyrosyl-DNA Phosphodiesterase 1 as a potential biomarker in cancer therapy.

Mona's undergraduate degree is in arid-zone agriculture. She specialized in plant breeding and genetics and developed improved wheat varieties. Mona also studied food technology, soil sciences, plant pathology, animal husbandry, agronomy, entomology and horticulture.



# MONA MALIK, PhD

## SENIOR TECHNICAL ADVISOR AND PATENT AGENT

### Professional

- Patent Agent, Hahn Loeser & Parks LLP, 2015 to present
- Technical Advisor & Patent Agent, Husch Blackwell LLP, 2009-15
- Faculty Member and Research Associate, University of Pennsylvania, Department of Pulmonary, Allergy and Critical Care at the School of Medicine, 2006-09
- Postdoctoral Research Assistant, St. Jude Children's Research Hospital, Department of Molecular Pharmacology, 2000-06

### Admissions

- U.S. Patent and Trademark Office, 2012 (Registration Number: 69135)

### Recognition

- American Association for Cancer Research, Pfizer Scholar in Cancer Research Award, 2001
- British Federation of Women Graduates Award, 1998-1999
- Charles Wallace Trust Award, 1998-1999
- Raymond and Beverly Sackler Award, 1997-1998

### Associations

- Cambridge Commonwealth Society: Fellow
- University of Cambridge Alumni Association: Life Member

### Publications

- Co-author, "An Arrestin-dependent multi-kinase signaling complex mediates MIP-1 $\beta$ /CCL4 signaling and chemotaxis of primary human macrophages," *Journal of Leukocyte Biology*, Volume 86, Pages 833-845, 2009.
- Co-author, "Monocyte Migration and LFA-1-Mediated Attachment to Brain Microvascular Endothelia is Regulated by SDF-1 $\alpha$  through Lyn Kinase," *Journal of Immunology*, 181(7), Pages 4632-4637, 2008.

- Co-author, "BCR-ABL1 Alters SDF-1 $\alpha$ -Mediated Adhesive Responses through the Beta2 Integrin LFA-1 in Leukemia Cells," *Blood*, 111(10), Pages 5182-5186, 2008.
- Co-author, "Tyrosyl-DNA Phosphodiesterase (Tdp1) Participates in the Repair of Top2-Mediated DNA Damage," *Proceedings of the National Academy of Sciences of the United States of America*, 103(24), Pages 8953-8958, 2006.
- Co-author, "Roles of Non-Homologous End-Joining Pathways in Surviving Topoisomerase II-Mediated DNA Damage," *Molecular Cancer Therapeutics*, 5(6), Pages 1405-1414, 2006.
- Co-author, "DNA Repair Functions that Control Sensitivity to Topoisomerase-Targeting Drugs," *Eukaryotic Cell*, 3(1), Pages 82-90, 2004.
- Co-author, "DNA Topoisomerase in Cancer Therapy - Present and Future," Andoh, T., ed., *Kluwer Academic*, New York, Chapter 6, Pages 109-128, 2003.
- Co-author, "Study of Heritability and Genetic Advances in Wheat Crosses," *Journal of Agriculture Research*, 33 (4), Pages 235-239, 1995.

### Speaking Engagements

- Speaker, American Society of Hematology annual meeting, Atlanta, Ga., 2007.
- Speaker, American Association for Cancer Research annual meetings, Washington, D.C., and Anaheim, Calif., 2006 and 2005.
- Speaker, National Cancer Institute, European Organization for Research and Treatment of Cancer, Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 2004.

### Education

- University of Cambridge (UK), Ph.D., Department of Genetics, 1999
- University of Agriculture, B.S. in Agriculture, with honors, 1994